R. D. Idbaih, A. Ducray, F. Lahutte, M. Hoang-xuan, K. Delattre et al., Primary brain tumours in adults, The Lancet, vol.379, pp.1984-1996, 2012.

M. J. Van-den-bent, Chemotherapy for low-grade glioma, Current Opinion in Neurology, vol.28, issue.6, pp.633-938, 2015.
DOI : 10.1097/WCO.0000000000000257

R. D. Kaloshi, G. Amiel-benouaich, A. Lejeune, J. Marie, Y. Mandonnet et al., Dynamic history of low-grade gliomas before and after temozolomide treatment, Annals of Neurology, vol.61, pp.484-90, 2007.

H. F. Thuijl, . Van, T. Mazor, B. E. Johnson, S. D. Fouse et al., Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment, Acta Neuropathologica, vol.15, issue.4, pp.597-607, 2015.
DOI : 10.1158/1078-0432.CCR-08-3012

S. Yip, J. Miao, D. P. Cahill, A. J. Iafrate, K. Aldape et al., MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance, Clinical Cancer Research, vol.15, issue.14, pp.4622-4629, 2009.
DOI : 10.1158/1078-0432.CCR-08-3012

R. Mclendon, A. Friedman, D. Bigner, E. G. Van-meir, D. J. Brat et al., Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, vol.123, issue.7216, pp.1061-1068, 2008.
DOI : 10.2174/187152008784220276

C. Hunter, R. Smith, D. P. Cahill, P. Stephens, C. Stevens et al., Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy, Cancer Research, vol.66, issue.8, pp.3987-3991, 2006.
DOI : 10.1158/0008-5472.CAN-06-0127

D. P. Cahill, K. K. Levine, R. A. Betensky, P. J. Codd, C. A. Romany et al., Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment, Clinical Cancer Research, vol.13, issue.7, pp.2038-2045, 2007.
DOI : 10.1158/1078-0432.CCR-06-2149

G. J. Kitange, B. L. Carlson, M. A. Schroeder, P. T. Grogan, J. D. Lamont et al., Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts, Neuro-Oncology, vol.11, issue.3, p.11, 2009.
DOI : 10.1215/15228517-2008-090

G. Kaloshi, A. Benouaich-amiel, F. Diakite, S. Taillibert, J. Lejeune et al., Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome, Neurology, vol.68, issue.21, pp.1831-1836, 2007.
DOI : 10.1212/01.wnl.0000262034.26310.a2

S. Ostermann, C. Csajka, T. Buclin, S. Leyvraz, F. Lejeune et al., Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients, Clinical Cancer Research, vol.10, issue.11, pp.3728-3736, 2004.
DOI : 10.1158/1078-0432.CCR-03-0807

B. Ribba, G. Kaloshi, M. Peyre, D. Ricard, V. Calvez et al., A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy, Clinical Cancer Research, vol.18, issue.18, pp.5071-5080, 2012.
DOI : 10.1158/1078-0432.CCR-12-0084
URL : https://hal.archives-ouvertes.fr/hal-00744626

C. Mbogning, K. Bleakley, and M. Lavielle, Between-subject and within-subject model mixtures for classifying hiv treatment response, Prog. Appl. Math, vol.4, pp.148-166, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00756615

T. Shiiki, Y. Hashimoto, and K. I. Inui, Simulation for population pharmacodynamic analysis of dose-ranging trials: usefulness of the mixture model analysis for detecting nonresponders, Pharmaceutical Research, vol.19, issue.6, pp.909-913, 2002.
DOI : 10.1023/A:1016181505556

E. Ollier, S. Hodin, T. Basset, S. Accassat, L. Bertoletti et al., In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors, Fundamental & Clinical Pharmacology, vol.13, issue.6, pp.604-614, 2015.
DOI : 10.1111/jth.12823

M. Lavielle and C. Mbogning, An improved SAEM algorithm for maximum likelihood estimation in mixtures of non linear mixed effects models, Statistics and Computing, vol.85, issue.433, pp.693-707, 2014.
DOI : 10.1080/01621459.1990.10474930
URL : https://hal.archives-ouvertes.fr/hal-00916817

. Lixoft-incuballiance, Monolix User Guide Version 4.3.3. 2014; Available from, 2015.

R. M. Savic and M. O. Karlsson, Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions, The AAPS Journal, vol.11, issue.3, pp.558-569, 2009.
DOI : 10.1208/s12248-009-9133-0

H. Wickham, ggplot2: elegant graphics for data analysis, 2009.

R. Development and C. Team, R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2012.

A. Sostelly, L. Payen, J. Guitton, D. Pietro, A. Falson et al., Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model, Fundamental & Clinical Pharmacology, vol.290, issue.2, pp.161-169, 2014.
DOI : 10.1007/s002800050656

J. Foo, J. Chmielecki, W. Pao, and F. Michor, Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer, Journal of Thoracic Oncology, vol.7, issue.10, pp.1583-1593, 2012.
DOI : 10.1097/JTO.0b013e31826146ee

B. Birkhead, E. Rankin, S. Gallivan, L. Dones, and R. Rubens, A mathematical model of the development of drug resistance to cancer chemotherapy, Eur. J. Cancer Clin

C. Tomasetti and D. Levy, Role of symmetric and asymmetric division of stem cells in developing drug resistance, Proceedings of the National Academy of Sciences, vol.77, issue.1, pp.16766-16771, 2010.
DOI : 10.1016/j.tpb.2009.10.008

N. Komarova, Stochastic modeling of drug resistance in cancer, Journal of Theoretical Biology, vol.239, issue.3, pp.351-366, 2006.
DOI : 10.1016/j.jtbi.2005.08.003

N. Terranova, P. Girard, U. Klinkhardt, and A. Munafo, Resistance Development: A Major Piece in the Jigsaw Puzzle of Tumor Size Modeling, CPT: Pharmacometrics & Systems Pharmacology, vol.7, issue.6, pp.320-323, 2015.
DOI : 10.1038/nrc2256

P. Mazzocco, C. Barthélémy, G. Kaloshi, M. Lavielle, D. Ricard et al., Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics, CPT: Pharmacometrics & Systems Pharmacology, vol.82, issue.12, pp.728-737, 2015.
DOI : 10.1038/sj.clpt.6100241
URL : https://hal.archives-ouvertes.fr/hal-01252076

T. Mazor, B. E. Johnson, M. Grimmer, C. Hong, E. G. Hamilton et al., Hypermutation and malignant progression in an expanded cohort of temozolomidetreated low-grade glioma patients, Neuro Oncol, vol.5, pp.17-97, 2015.

Y. Takagi, M. Hidaka, M. Sanada, H. Yoshida, and M. Sekiguchi, Different initial steps of apoptosis induced by two types of antineoplastic drugs, Biochemical Pharmacology, vol.76, issue.3, pp.303-311, 2008.
DOI : 10.1016/j.bcp.2008.05.008

M. Sanada, M. Hidaka, Y. Takagi, T. Y. Takano, Y. Nakatsu et al., Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis, Carcinogenesis, vol.28, issue.12, pp.2657-2663, 2007.
DOI : 10.1093/carcin/bgm188

W. J. Bodell, N. W. Gaikwad, D. Miller, and M. S. Berger, Formation of DNA adducts and induction of lacI mutations in big blue rat-2 cells treated with temozolomide implications for the treatment of low-grade adult and pediatric brain tumours, Cancer Epidemiology Biomarkers & Prevention, vol.12, pp.545-551, 2003.

M. J. Van-den-bent, Chemotherapy for low-grade glioma, Current Opinion in Neurology, vol.28, issue.6, pp.633-938, 2015.
DOI : 10.1097/WCO.0000000000000257